Skip to content
10-K

Annual Report

INNOVUS PHARMACEUTICALS, INC.

0001437749-19-006219

← back to feed
Filed
Apr 1, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2018 · Apr 1, 2019 2.36M sh
Capex FY 2018 · Dec 31, 2018 $238K
Capex restated FY 2018 · Dec 31, 2017 $45K
Operating Cash Flow FY 2018 · Dec 31, 2018 −$6.12M
Operating Cash Flow restated FY 2018 · Dec 31, 2017 −$2.36M
Short Term Debt FY 2018 · Dec 31, 2018 $3.07M
Short Term Debt FY 2018 · Dec 31, 2017 $1.24M
Stockholders Equity FY 2018 · Dec 31, 2018 $109K
Stockholders Equity restated FY 2018 · Dec 31, 2017 $903K
Stockholders Equity restated FY 2018 · Dec 31, 2016 $1.09M
Current Liabilities FY 2018 · Dec 31, 2018 $7.35M
Current Liabilities restated FY 2018 · Dec 31, 2017 $5.15M
Total Liabilities FY 2018 · Dec 31, 2018 $10.02M
Total Liabilities restated FY 2018 · Dec 31, 2017 $8.13M
Current Assets FY 2018 · Dec 31, 2018 $5.02M
Current Assets restated FY 2018 · Dec 31, 2017 $3.72M
Total Assets FY 2018 · Dec 31, 2018 $10.13M
Total Assets restated FY 2018 · Dec 31, 2017 $9.03M
Sga Expense FY 2018 · Dec 31, 2018 $7.99M
Sga Expense restated FY 2018 · Dec 31, 2017 $5.18M
Rd Expense FY 2018 · Dec 31, 2018 $160K
Rd Expense restated FY 2018 · Dec 31, 2017 $39K
Net Income FY 2018 · Dec 31, 2018 −$8.28M
Net Income restated FY 2018 · Dec 31, 2017 −$6.5M
Operating Income FY 2018 · Dec 31, 2018 −$5.69M
Operating Income restated FY 2018 · Dec 31, 2017 −$5.1M
Cost Of Revenue FY 2018 · Dec 31, 2018 $4.33M
Cost Of Revenue FY 2018 · Dec 31, 2017 $1.85M
Revenue FY 2018 · Dec 31, 2018 $23.99M
Revenue FY 2018 · Dec 31, 2017 $8.82M